Cargando…

Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review

The Hepatic CHEMOSAT(®) Delivery System is an innovative medical device for the treatment of patients with unresectable primary liver tumors or unresectable hepatic metastases from solid organ malignancies. This system is used to perform chemosaturation percutaneous hepatic perfusion (CS-PHP), a pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogel, Arndt, Gupta, Sanjay, Zeile, Martin, von Haken, Rebecca, Brüning, Roland, Lotz, Gösta, Vahrmeijer, Alexander, Vogl, Thomas, Wacker, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126197/ https://www.ncbi.nlm.nih.gov/pubmed/27798773 http://dx.doi.org/10.1007/s12325-016-0424-4

Ejemplares similares

Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma
por: Schönfeld, Leon, et al.
Publicado: (2020)

New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option
por: Dewald, Cornelia L. A., et al.
Publicado: (2022)

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma
por: Modi, Sachin, et al.
Publicado: (2022)

Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department
por: Öcal, Osman, et al.
Publicado: (2021)

Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience
por: Artzner, Christoph, et al.
Publicado: (2019)

Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma
por: Teal, Lindsey, et al.
Publicado: (2021)

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience
por: Dewald, Cornelia L. A., et al.
Publicado: (2021)

Heparin reversal with protamine sulfate after Percutaneous Hepatic Perfusion (PHP): is less more?
por: Facchetti, Nadia, et al.
Publicado: (2023)

Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study
por: Kolb, Manuel, et al.
Publicado: (2023)

Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery
por: Dewald, C. L. A., et al.
Publicado: (2020)

Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
por: Struck, Manuel Florian, et al.
Publicado: (2023)

Radial Artery Access for Hepatic Chemosaturation: The First Description of Technical Feasibility
por: Frost, Joshua P, et al.
Publicado: (2021)

Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
por: Brüning, R., et al.
Publicado: (2020)

Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies
por: Burgmans, Mark C., et al.
Publicado: (2015)

Analysis of patient’s X-ray exposure in hepatic chemosaturation procedures: a single center experience
por: Ebel, Sebastian, et al.
Publicado: (2022)

Anästhesiologisches und postinterventionelles Management bei perkutaner hepatischer Melphalanperfusion (Chemosaturation)
por: Kliem, Peter, et al.
Publicado: (2022)

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
por: Tong, T. M. L., et al.
Publicado: (2022)

Thrombotischer Verschluss der extrakorporalen Zirkulation während hepatischer Chemosaturation trotz zielgerechter Antikoagulation: Ein Fallbericht
por: Kuhner, M., et al.
Publicado: (2022)

Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer
por: Meijer, T. Susanna, et al.
Publicado: (2022)

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases
por: Bethlehem, Martijn S., et al.
Publicado: (2021)

Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017)

Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease
por: Karydis, Ioannis, et al.
Publicado: (2017)

Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017)

Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial
por: Meijer, T. Susanna, et al.
Publicado: (2019)

ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Feasibility of flow-related enhancement brain perfusion MRI
por: Glandorf, Julian, et al.
Publicado: (2022)

Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases
por: van Iersel, Liselot B. J., et al.
Publicado: (2008)

A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Versorgung älterer Patienten nach dem Krankenhausaufenthalt
por: Zeile, Thomas
Publicado: (2021)

Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
por: Carr, Michael J., et al.
Publicado: (2020)

Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
por: Veelken, Rhea, et al.
Publicado: (2021)

Percutaneous Management of Pyogenic Hepatic Abscesses
por: Andersson, Roland, et al.
Publicado: (1990)

Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery
por: Struck, Manuel Florian, et al.
Publicado: (2021)

Influence of gadolinium, field-strength and sequence type on quantified perfusion values in phase-resolved functional lung MRI
por: Glandorf, Julian, et al.
Publicado: (2023)

Comparison of phase-resolved functional lung (PREFUL) MRI derived perfusion and ventilation parameters at 1.5T and 3T in healthy volunteers
por: Glandorf, Julian, et al.
Publicado: (2020)

Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
por: Moeslein, Fred M., et al.
Publicado: (2014)

MRI manifestations of hepatic perfusion disorders
por: Cao, Qing-Yong, et al.
Publicado: (2018)

Research progress on hepatic machine perfusion
por: Gao, Junda, et al.
Publicado: (2021)

Comparison of dual-energy computer tomography and dynamic contrast-enhanced MRI for evaluating lung perfusion defects in chronic thromboembolic pulmonary hypertension
por: Moher Alsady, Tawfik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kg1safb20daah9ts2r6v3dfg5h